Photo from Harpreet Singh/LinkedIn
Aug 17, 2024, 09:13
Harpreet Singh: Exciting news in colorectal cancer treatment
Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn:
“Exciting news in colorectal cancer treatment! The FDA has granted accelerated approval for adagrasib + cetuximab, targeting KRAS G12C mutations.
Key takeaways from my latest video:
- First KRAS G12C targeting drug approved for colorectal cancer
- 34% overall response rate in the KRYSTAL-1 trial
- Addresses ~4% of colorectal cancer patients with this specific mutation
- KRAS was previously considered ‘undruggable’ in this cancer type
- This approval marks a significant step forward in precision medicine for colorectal cancer.
The KRYSTAL-10 confirmatory trial is now fully enrolled, and its results could potentially convert this to a full FDA approval.
What are your thoughts on targeting previously ‘undruggable’ mutations? What impact do you see long-term?
Follow for more.”
Proceed to the video attached to the post.
Source: Harpreet Singh/LinkedIn
More posts by Harpreet Singh in OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 26, 2024, 14:47
Dec 26, 2024, 14:44